Table 3 Sub-group analysis for survival outcomes in patients based on prognostic factors and therapy
From: Natural history of multiple myeloma with de novo del(17p)
Survival outcomes and subgroups | De novo del(17p) | High-risk translocation | Standard-risk | P a |
|---|---|---|---|---|
Progression free survival, (months) | ||||
Age <65 years (n = 487) | 21.0 (16.8–27.0) | 25.4 (17.5–32.6) | 32.3 (28.7–37.7) | 0.176; <0.001 |
Age ≥65 years (n = 443) | 21.3 (16.0–25.8) | 16.6 (11.2–25.5) | 27.4 (25.3–30.6) | 0.520; 0.002 |
ISS I/II (n = 541) | 27.0 (21.1–30.3) | 24.6 (17.1–31.5) | 30.9 (29.1–34.8) | 0.699; 0.002 |
ISS III (n = 265) | 14.3 (9.6–16.9) | 16.7 (5.1–34.4) | 24.8 (19.7–28.5) | 0.212; <0.001 |
PI-containing induction (n = 557) | 22.6 (18.4–27.5) | 25.0 (18.1–32.6) | 29.5 (26.3–31.8) | 0.336; <0.001 |
Others (n = 371) | 16.1 (13.8–22.0) | 13.3 (5.1–25.5) | 30.6 (27.1–33.8) | 0.840; <0.001 |
Normal LDH (n = 556) | 22.5 (18.4–28.2) | 18.4 (15.1–25.4) | 30.8 (28.0–33.1) | 0.241; <0.001 |
High LDH (n = 115) | 16.1 (8.3–17.9) | 6.7 (1.5–21.9) | 27.1 (18.3–32.3) | 0.245; <0.001 |
Low PC proliferative rate (n = 405) | 22.3 (17.8–28.8) | 16.6 (13.3–22.0) | 29.8 (26.3–32.1) | 0.106; 0.044 |
High PC proliferative rate (n = 101) | 10.4 (5.1–18.6) | 6.7 (2.3–17.1) | 25.0 (17.9–31.3) | 0.264; <0.001 |
Overall survival, (months) | ||||
Age < 65 years (n = 487) | 55.2 (42.0–67.4) | 81.6 (60.5-NR) | 130.6 (112.6-NR) | 0.030; <0.001 |
Age ≥ 65 years (n = 443) | 44.7 (37.5–54.6) | 67.1 (25.2-NR) | 78.6 (70.4–103.6) | 0.201; <0.001 |
ISS I/II (n = 541) | 58.3 (45.3–71.8) | 81.6 (60.5-NR) | 112.3 (103.6-NR) | 0.039; <0.001 |
ISS III (n = 265) | 33.3 (23.2–44.7) | 38.7 (21.1-NR) | 64.7 (59.6–124.4) | 0.179; <0.001 |
Normal LDH (n = 556) | 53.9 (43.9–65.9) | 67.1 (38.7–81.6) | 105.0 (83.9–125.6) | 0.322; <0.001 |
High LDH (n = 115) | 26.8 (18.6–46.4) | NR (7.3-NR) | 106.1 (71.7-NR) | 0.295; <0.001 |
Low PC proliferative rate (n = 405) | 47.8 (41.6–67.4) | 72.3 (38.7-NR) | 103.6 (80.4–130.6) | 0.144; <0.001 |
High PC proliferative rate (n = 101) | 32.9 (15.2–54.9) | 21.5 (7.6–28.0) | 62.5 (42.7–85.9) | 0.217; 0.008 |
PI-containing induction (n = 557) | 54.3 (40.7–62.6) | NR (54.0-NR) | 124.4 (79.9-NR) | 0.007; <0.001 |
Others (n = 371) | 45.2 (36.5–58.3) | 67.1 (27.5–85.4) | 106.1 (84.8–125.6) | 0.405; <0.001 |
Early SCT (n = 466) | 54.9 (45.3–66.5) | 85.4 (72.3-NR) | 130.6 (106.1-NR) | 0.038; <0.001 |
Delayed or no SCT (n = 150) | 77.2 (44.6-NR) | NR (38.7-NR) | 125.6 (105.6-NR) | 0.289; 0.001 |
